Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice - PubMed (original) (raw)
Comparative Study
. 2006 Jul;318(1):173-85.
doi: 10.1124/jpet.106.102046. Epub 2006 Apr 11.
Affiliations
- PMID: 16608916
- DOI: 10.1124/jpet.106.102046
Comparative Study
Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice
Ruggero Galici et al. J Pharmacol Exp Ther. 2006 Jul.
Abstract
Previous studies indicate that agonists of the group II metabotropic glutamate receptors (mGluRs), mGluR2 and mGluR3, may provide a novel approach for the treatment of anxiety disorders and schizophrenia. However, the relative contributions of the mGluR2 and mGluR3 subtypes to the effects of the group II mGluR agonists remain unclear. In the present study, we describe an alternate synthesis and further pharmacological characterization of a recently reported positive allosteric modulator of mGluR2 termed biphenyl-indanone A (BINA). In recombinant systems, BINA produced a robust and selective potentiation of the response of mGluR2 to glutamate with no effect on the glutamate response of other mGluR subtypes. In hippocampal brain slices, BINA (1 microM) significantly potentiated the mGluR2/3 agonist-induced inhibition of excitatory synaptic transmission at the medial perforant path-dentate gyrus synapse. BINA was also efficacious in several models predictive of antipsychotic- and anxiolytic-like activity in mice. The behavioral effects of BINA were blocked by the mGluR2/3 antagonist (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495), suggesting that the in vivo effects of BINA are mediated by increased activation of mGluR2. Collectively, these results indicate that BINA is a selective mGluR2 positive allosteric modulator and provide further support for the growing evidence that selective allosteric potentiators of mGluR2 mimic many of the in vivo actions of mGluR2/3 agonists that may predict therapeutic utility of these compounds.
Similar articles
- Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
Satow A, Maehara S, Ise S, Hikichi H, Fukushima M, Suzuki G, Kimura T, Tanak T, Ito S, Kawamoto H, Ohta H. Satow A, et al. J Pharmacol Exp Ther. 2008 Aug;326(2):577-86. doi: 10.1124/jpet.108.138107. Epub 2008 May 16. J Pharmacol Exp Ther. 2008. PMID: 18487514 - A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E. Benneyworth MA, et al. Mol Pharmacol. 2007 Aug;72(2):477-84. doi: 10.1124/mol.107.035170. Epub 2007 May 25. Mol Pharmacol. 2007. PMID: 17526600 - A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.
Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL Jr. Kinney GG, et al. J Pharmacol Exp Ther. 2005 Apr;313(1):199-206. doi: 10.1124/jpet.104.079244. Epub 2004 Dec 17. J Pharmacol Exp Ther. 2005. PMID: 15608073 - Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia.
Fraley ME. Fraley ME. Expert Opin Ther Pat. 2009 Sep;19(9):1259-75. doi: 10.1517/13543770903045009. Expert Opin Ther Pat. 2009. PMID: 19552508 Review. - Role of metabotropic glutamate receptors in the control of neuroendocrine function.
Durand D, Pampillo M, Caruso C, Lasaga M. Durand D, et al. Neuropharmacology. 2008 Sep;55(4):577-83. doi: 10.1016/j.neuropharm.2008.06.022. Epub 2008 Jun 20. Neuropharmacology. 2008. PMID: 18616955 Review.
Cited by
- Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction.
Walker AG, Wenthur CJ, Xiang Z, Rook JM, Emmitte KA, Niswender CM, Lindsley CW, Conn PJ. Walker AG, et al. Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1196-201. doi: 10.1073/pnas.1416196112. Epub 2015 Jan 12. Proc Natl Acad Sci U S A. 2015. PMID: 25583490 Free PMC article. - Therapeutic potential of metabotropic glutamate receptor modulators.
Hovelsø N, Sotty F, Montezinho LP, Pinheiro PS, Herrik KF, Mørk A. Hovelsø N, et al. Curr Neuropharmacol. 2012 Mar;10(1):12-48. doi: 10.2174/157015912799362805. Curr Neuropharmacol. 2012. PMID: 22942876 Free PMC article. - Beyond dopamine: glutamate as a target for future antipsychotics.
Sendt KV, Giaroli G, Tracy DK. Sendt KV, et al. ISRN Pharmacol. 2012;2012:427267. doi: 10.5402/2012/427267. Epub 2012 Jul 5. ISRN Pharmacol. 2012. PMID: 22830044 Free PMC article. - Design, Synthesis, and Characterization of [18F]mG2P026 as a High-Contrast PET Imaging Ligand for Metabotropic Glutamate Receptor 2.
Yuan G, Dhaynaut M, Guehl NJ, Afshar S, Huynh D, Moon SH, Iyengar SM, Jain MK, Pickett JE, Kang HJ, Ondrechen MJ, El Fakhri G, Normandin MD, Brownell AL. Yuan G, et al. J Med Chem. 2022 Jul 28;65(14):9939-9954. doi: 10.1021/acs.jmedchem.2c00593. Epub 2022 Jul 8. J Med Chem. 2022. PMID: 35802702 Free PMC article. - Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
Conn PJ, Lindsley CW, Jones CK. Conn PJ, et al. Trends Pharmacol Sci. 2009 Jan;30(1):25-31. doi: 10.1016/j.tips.2008.10.006. Epub 2008 Dec 6. Trends Pharmacol Sci. 2009. PMID: 19058862 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources